In-vitro evaluation of miR-101-5P effect on herpes simplex virus replication

Piroozmand, A. and Sadegh-Ehdaei, B. and Shabani, M. and Moghim, S. and Mirzaei, A. and Mouhebat, L. (2018) In-vitro evaluation of miR-101-5P effect on herpes simplex virus replication. Journal of Isfahan Medical School, 36 (494). pp. 1024-1029.

[img] Text

Download (61kB)
Official URL:


Background: Herpes simplex virus type 1 (HSV-1) is known worldwide for its serious disease and a kind of infection that involves nervous system throughout human lifelong. HSV-1 infection is much more considerable in immunocompromised patients and due to the growing resistance to its main drug, acyclovir, alternative treatments are required. MicroRNAs (miRNAs) regulate host and viral gene expression, post-transcriptionally. One previous study has shown that mir-101-3p expression may play role in HSV-1-infected cells. Methods: In this study, synthesized mimic hsa-miR-101-5p was transfected to HSV-1-infected Hela cells to observe its effect on HSV-1 replication via microscopic observation. Findings: Hela cells transfected by hsa-miR-101-5p produced less viral progeny, and expressed less cytopathic effects. Conclusion: Considering the effect of hsa-miR-101 in suppressing HSV-1 replication without affecting cell viability, this achievement can give us new insights in treatment of HSV-1 infection. © 2018, Isfahan University of Medical Sciences(IUMS). All rights reserved.

Item Type: Article
Additional Information: cited By 0
Uncontrolled Keywords: microRNA 101; microRNA 101 5p; unclassified drug, Article; cell viability; controlled study; cytopathogenic effect; genetic transfection; HeLa cell line; herpes simplex; human; Human alphaherpesvirus 1; human cell; in vitro study; microscopy; progeny; viral gene delivery system; virus inhibition; virus replication
Subjects: Immunology and Microbiology
Divisions: Faculty of Medicine > Basic Sciences > Department of Microbiology & Immunology
Depositing User: ART . editor
Date Deposited: 23 Apr 2019 09:40
Last Modified: 23 Apr 2019 09:40

Actions (login required)

View Item View Item